Peripheral neuropathy, characterized by numbness or paresthesia of an extremity, has been reported in patients treated with systemic metronidazole. Although not evident in clinical trials for topical metronidazole, peripheral neuropathy has been reported with the post-approval use. These highlights do not include all the information needed to use METROGEL (metronidazole) Gel, 1% safely and effectively. See full prescribing information for METROGEL (metronidazole) Gel, 1%.

**ADVERSE REACTIONS**

Most common adverse reactions (incidence ≥3%) are nasal irritation, upper respiratory tract infection, and headache. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Gallela Laboratories, L.P. at 1-866-739-4137 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch

---

### TABLE 1: Adverse Reactions That Occurred at a Rate of ≥3%

<table>
<thead>
<tr>
<th>System Organ Class/Preferred Term</th>
<th>Metronidazole Gel, 1%</th>
<th>Gel Vehicle</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total N=189</td>
<td>189 (100.0)</td>
<td>189 (100.0)</td>
</tr>
<tr>
<td>Most common adverse reactions</td>
<td>189 (100.0)</td>
<td>189 (100.0)</td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>189 (100.0)</td>
<td>189 (100.0)</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>17 (9.1)</td>
<td>8 (4.2)</td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>18 (9.5)</td>
<td>8 (4.2)</td>
</tr>
<tr>
<td>Nasal congestion</td>
<td>6 (3.2)</td>
<td>3 (1.6)</td>
</tr>
<tr>
<td>Vaginal mycosis</td>
<td>1 (0.5)</td>
<td>1 (0.5)</td>
</tr>
<tr>
<td>Vaginal disorders</td>
<td>1 (0.5)</td>
<td>1 (0.5)</td>
</tr>
<tr>
<td>Nasal irritation</td>
<td>1 (0.5)</td>
<td>1 (0.5)</td>
</tr>
</tbody>
</table>

---

### TABLE 2: Local Cutaneous Signs and Symptoms of Irritation That Were Worse Than Baseline

<table>
<thead>
<tr>
<th>Sign/Symptom</th>
<th>Metronidazole Gel, 1%</th>
<th>Gel Vehicle</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scaling</td>
<td>134 (71.4)</td>
<td>51 (27.1)</td>
</tr>
<tr>
<td>Pruritus</td>
<td>88 (46.9)</td>
<td>44 (23.2)</td>
</tr>
<tr>
<td>Redness</td>
<td>56 (29.7)</td>
<td>30 (15.9)</td>
</tr>
<tr>
<td>Scaling</td>
<td>56 (29.7)</td>
<td>30 (15.9)</td>
</tr>
<tr>
<td>Itching</td>
<td>56 (29.7)</td>
<td>30 (15.9)</td>
</tr>
<tr>
<td>Seborrhea</td>
<td>56 (29.7)</td>
<td>30 (15.9)</td>
</tr>
<tr>
<td>Pruritus</td>
<td>56 (29.7)</td>
<td>30 (15.9)</td>
</tr>
</tbody>
</table>

---

### TABLE 3: Lab Tests

No abnormalities were observed in any laboratory test in patients treated with metronidazole Gel, 1% or Gel Vehicle.

---

### DOSAGE AND ADMINISTRATION

Apply and rub in a thin film of METROGEL once daily to affected area(s). (2)

Cosmetics may be applied after the application of METROGEL. (2)

---

### CONTRAINDICATIONS

METROGEL is contraindicated in those patients with a history of hypersensitivity to metronidazole or to any other ingredient in the formulation. (4)

---

### WARNINGS AND PRECAUTIONS

Peripheral neuropathy, characterized by numbness or paresthesia of an extremity has been reported in patients treated with systemic metronidazole. Although not evident in clinical trials for topical metronidazole, peripheral neuropathy has been reported with the post-approval use. The appearance of abnormal neurologic signs should prompt immediate reevaluation of METROGEL therapy. Metronidazole should be administered with caution to patients with central nervous system diseases.

---

### ADVERSE REACTIONS

Most common adverse reactions (incidence ≥3%) are nasal irritation, upper respiratory tract infection, and headache. (6)

---

### DRUG INTERACTIONS

Drug interactions should be kept in mind when METROGEL is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical metronidazole administration because of low absorption. (7)

---

### TABLE 1: Adverse Reactions That Occurred at a Rate of ≥3%

<table>
<thead>
<tr>
<th>System Organ Class/Preferred Term</th>
<th>Metronidazole Gel, 1%</th>
<th>Gel Vehicle</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total N=189</td>
<td>189 (100.0)</td>
<td>189 (100.0)</td>
</tr>
<tr>
<td>Most common adverse reactions</td>
<td>189 (100.0)</td>
<td>189 (100.0)</td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>189 (100.0)</td>
<td>189 (100.0)</td>
</tr>
<tr>
<td>Nasopharyngitis</td>
<td>17 (9.1)</td>
<td>8 (4.2)</td>
</tr>
<tr>
<td>Upper respiratory tract infection</td>
<td>18 (9.5)</td>
<td>8 (4.2)</td>
</tr>
<tr>
<td>Nasal congestion</td>
<td>6 (3.2)</td>
<td>3 (1.6)</td>
</tr>
<tr>
<td>Vaginal mycosis</td>
<td>1 (0.5)</td>
<td>1 (0.5)</td>
</tr>
<tr>
<td>Vaginal disorders</td>
<td>1 (0.5)</td>
<td>1 (0.5)</td>
</tr>
<tr>
<td>Nasal irritation</td>
<td>1 (0.5)</td>
<td>1 (0.5)</td>
</tr>
</tbody>
</table>

---

### TABLE 2: Local Cutaneous Signs and Symptoms of Irritation That Were Worse Than Baseline

<table>
<thead>
<tr>
<th>Sign/Symptom</th>
<th>Metronidazole Gel, 1%</th>
<th>Gel Vehicle</th>
</tr>
</thead>
<tbody>
<tr>
<td>Scaling</td>
<td>134 (71.4)</td>
<td>51 (27.1)</td>
</tr>
<tr>
<td>Pruritus</td>
<td>88 (46.9)</td>
<td>44 (23.2)</td>
</tr>
<tr>
<td>Redness</td>
<td>56 (29.7)</td>
<td>30 (15.9)</td>
</tr>
<tr>
<td>Scaling</td>
<td>56 (29.7)</td>
<td>30 (15.9)</td>
</tr>
<tr>
<td>Itching</td>
<td>56 (29.7)</td>
<td>30 (15.9)</td>
</tr>
<tr>
<td>Seborrhea</td>
<td>56 (29.7)</td>
<td>30 (15.9)</td>
</tr>
<tr>
<td>Pruritus</td>
<td>56 (29.7)</td>
<td>30 (15.9)</td>
</tr>
</tbody>
</table>

---

### LAB TESTS

No abnormalities were observed in any laboratory test in patients treated with metronidazole Gel, 1% or Gel Vehicle.
reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate the frequency or establish a causal relationship to drug exposure.

7 DRUG INTERACTIONS
Oral metronidazole has been reported to potentiate the anticoagulant effect of coumarin and warfarin, resulting in a prolongation of prothrombin time. Drug interactions should be kept in mind when METROGEL is prescribed for patients who are receiving anticoagulant treatment, although they are less likely to occur with topical metronidazole administration because of low absorption.

8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy
Teratogenic Effects: Pregnancy Category B.

There are no adequate and well-controlled studies with the use of METROGEL in pregnant women. Metronidazole crosses the placental barrier and enter the fetal circulation rapidly. No fetal toxicity was observed after oral administration of metronidazole in rats or mice at 100 and 20 times, respectively, the expected clinical dose. However, oral metronidazole has shown carcinogenic activity in rodents. Because animal reproduction studies are not always predictive of human response, METROGEL should be used during pregnancy only if clearly needed.

8.3 Nursing Mothers
After oral administration, metronidazole is secreted in breast milk in concentrations similar to those found in the plasma. Even though blood levels taken after topical metronidazole administration are significantly lower than those achieved after oral metronidazole a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother and the risk to the infant.

8.4 Pediatric Use
Safety and effectiveness in pediatric patients have not been established.

9 DESCRIPTION
METROGEL (metronidazole) Gel, 1% contains metronidazole, USP chemically, metronidazole is 2-methyl-5-nitro-1 H-imidazole-1-acetic acid. The molecular formula for metronidazole is C6H9N3O3. It has the following structural formula:

```
\[
\text{CH2CH2OH} \\
\text{H} \\
\text{H} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\
\text{J} \\...